MindBio Therapeutics (XCNQ:MBIO) Dividends per Share : C$0.00 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Dividends per Share?

MindBio Therapeutics's dividends per share for the three months ended in Mar. 2024 was C$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, MindBio Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

MindBio Therapeutics Dividends per Share Historical Data

The historical data trend for MindBio Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Dividends per Share Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Dividends per Share

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividends per Share	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of MindBio Therapeutics's Dividends per Share

For the Biotechnology subindustry, MindBio Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Dividend Yield % falls into.

MindBio Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

MindBio Therapeutics (XCNQ:MBIO) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

MindBio Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	0.001
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

MindBio Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.